The First-in-Human trial demonstrated that the novel challenge agent had high attack rates of up to 100%. (Image: iStock/bodym)

SGS completes Ph I trial of new influenza virus

By Melissa Fassbender

SGS has completed a Phase I clinical trial of a new influenza virus strain in healthy volunteers and has increased capacity at its Mississauga, Canada-based laboratory.

ABL is providing services as part of BARDA's Fill-Finish Manufacturing Network. (Image: iStock/BernardaSv)

ABL to fill live virus-based MCMs for BARDA

By Melissa Fassbender

ABL, Inc. will provide fill/finish services for live virus-based medical countermeasures (MCM) as part of the five-year contract worth up to $50m.

Elimiating Viruses the NanoViricides Way

Elimiating Viruses the NanoViricides Way

By Dan Stanton

NanoViricides' nanotech drug delivery platform has the potential to eliminate viruses, the firm says as construction began on a manufacturing facility to support upcoming clinical trials.


Follow us


View more


Featured Suppliers